• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Flow Sciences

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Adare Pharma Solutions

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services

    Aphena Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Bio-CMO Capacity Constraints

    What they’re doing about them

    Related CONTENT
    • A Potential “Marriage”
    • Injectables Firms Expand Capacity
    • Mogene
    • TFF Expands Engagement with Experic
    • India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    Eric Langer, BioPlan Associates09.05.13
    Capacity constraints are still a problem in the biomanufacturing industry, and almost six in 10 biomanufacturers are today facing at least minor constraints at some stage of manufacturing, according to data released in our 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1. But contract manufacturing organizations (CMOs) appear to be less afflicted by significant constraint issues than biotherapeutic developers, and it may well be that a focus on downstream innovation during the past three years is a reason why.


    Fig. 1: Capacity Constraints, Biotherapeutic Developers vs. CMOs

    We first look at how CMOs and biodevelopers stack up when it comes to capacity constraint issues. Data from our study, in which we surveyed 235 biopharma industry decision-makers, indicates that 57.9% of respondents are experiencing some level of constraints today. Most commonly, constraints are termed minor (24.6%) or moderate (20.2%), but about one in 8 are also feeling the effects of significant (8.3%) or severe (4.7%) constraints.

    Not surprisingly, it appears that CMOs are adjusting their operations more rapidly and flexibly to avoid capacity problems. When comparing biotherapeutic developers vs. CMOs, we found that most of the significant problems are limited to developers. That is, 14.7% of developers report that they are today experiencing significant (9.2%) or severe (5.5%) constraints. The tally for CMOs is zero experiencing severe constraints, and only 2.3% faced with significant constraints.

    The difference then lies almost wholly in their severity, with CMOs more likely to be seeing minor constraints and developers facing more serious problems. Because CMOs must necessarily have adequate capacity to meet the needs of their clients, this is to be expected.

    The implications to CMOs in this analysis, especially when comparing results over time, is that the CMOs that are able to anticipate under-capacity at biotherapeutic developers will be better prepared to ramp up their resources to capture new capacity-constrained clients.

    Capacity is a constantly moving target, and the data show a significant change from last year, when almost one in 5 CMOs said they were experiencing severe or significant constraints, versus 14.6% of biotherapeutic developers. In fact, both groups reported a similar incidence of constraints last year, but CMOs were more likely to be seeing the significant bottlenecks, while developers perceived theirs as being more moderate in nature.

    What Have CMOs Been Doing?
    It’s not entirely unexpected that CMOs express less overall capacity constraint concerns than product developers, as they’re simply not contracted by clients to assume tasks requiring manufacturing capacity beyond what they can deliver. Even so, last year’s data showed that CMOs can be subject to capacity constraint problems. So, what have CMOs been doing that may have alleviated their bottlenecks?


    Fig. 2: Selected Areas to Address to Avoid Capacity Constraints: Biomanufacturers v. CMOsSource: 10th Annual Report and Survey of Biopharmaceutical Manufacturing, April 2013, www.bioplanassociates.com/10th

    One significant factor has been improved efficiencies at the CMOs that can’t be matched as rapidly at most developers. This is seen both in upstream, and downstream operations, and is partly due to the larger number and variety of products being manufactured by CMOs. Improvements in bioprocessing generally occur first at CMOs, according to our study.  And this year, we may be seeing the impact of some of these improvements, as new technologies become mainstreamed.

    Michiel E. Ultee, Ph.D., CSO at Laureate Biopharmaceutical Services (Princeton, NJ), said, “One example of efficiency in upstream operations being implemented at CMOs is the wider application of single-use bioreactors. Instead of requiring three days to turn around a bioreactor, we can now do the same in one day using our 250- and 1000-liter single-use bioreactors. By eliminating time-consuming cleaning and validation we can get more runs per year. This has an immediate effect on capacity utilization.” Dr. Ultee also noted that similar efficiencies are being seen now in downstream operations, as technologies become more ‘plug-and-play,’ such as ion-exchange membrane technologies that result in time savings.

    How CMOs Are Avoiding Capacity Constraints
    This evolution in operational efficiencies at CMOs can be seen in the areas that CMOs prioritized last year. During the past 10 years, we have asked both CMOs and innovators what they considered to be the most important areas to address in order to avoid significant capacity constraints. Last year, we see that CMOs were most concerned with developing better downstream purification technologies, at a far greater rate than biotherapeutic developers (75% and 55%, respectively). They were also more likely to indicate that they could avoid bottlenecks by developing better-performing disposable, single-use products (60% vs. 45%) and developing more “modularized” production systems (55% vs. 33.8%). Clearly, in 2012 CMOs were disproportionately focused on innovation, with downstream purification technologies most in-demand.

    In comparison, this year we see priorities have changed slightly. Part of this is due to the reduction in capacity problems overall. For example, only 13.3% of CMOs say the development of more “modularized” production systems can help avoid future constraints, a retreat from last year’s 55%. (We note that 41.1% of biotherapeutic developers are continuing to evaluate this area today.) CMOs also appear to have a less urgent need for better-performing disposable, single-use products this year, with this factor slipping to sixth place (from second place last year) as a critical capacity factor to address.

    By contrast, CMOs are more interested this year in regulatory issues such as streamlining the FDA regulatory process (60% this year versus 35% last year) and standardizing international regulatory processes.

    Despite all of that, there’s one area that stands out as constant from last year: the development of better downstream purification technologies. That was once again the top potential solution for CMOs. It was also, again, a bigger priority for CMOs than biodevelopers.

    Taken in combination, the data from the most recent studies suggest that CMOs are placing their bets on downstream innovation as the way to solve their future capacity constraint issues. While it’s somewhat of a stretch to suggest that this focus on innovation has led to an easing of bottlenecks, CMOs can act as a crucial lead indicator of the importance of various areas for biomanufacturing performance, and their continued focus on innovation — as other areas have become less prioritized — is a significant point of note.

    Five-Year Projections
    In this year’s study, none of the CMOs we surveyed believe their organization will experience “severe” constraints in five years’ time. As noted above, that may be due to the nature of CMOs that they do not assume tasks beyond their capacity and thus rarely encounter constraints of that severity. Or, if they did have any “severe” future concerns, these would be addressed with capacity expansion, which is increasingly easier to accomplish with single-use systems.

    Still, 15.6% of CMOs expect to see “significant” capacity constraints in 2018, a larger proportion than the 2.3% experiencing them today. And yet again, CMOs feel that they’re less likely to be feeling the pinch than biomanufacturers, 72.3% of whom expect to have bottlenecks in 2018, including almost 1 in 5 (18.8%) who believe those bottlenecks will be “severe” or “significant.”
    Future capacity constraints may be foreseen due to companies now expanding their R&D, companies’ product pipelines seeing success and progressing to larger-scale, and/or respondents presuming that some current equipment will be obsolete five years from now. Concerns about production constraints likely encourage higher facilities utilization, increased competition for access to CMOs and support higher CMO prices and profits.

    However, should serious CMO production constraints actually develop, this will obviously not be good for the industry and client companies currently using or planning to use CMOs. Luckily, higher yields and increasing use and increasing capacity of single-use/disposable bioreactor-based bioprocessing systems can be expected to limit major shortfalls in CMO and overall industry capacity, particularly for pre-commercial manufacture and as these graduate to assuming more commercial product manufacture.

    Factors Causing Future Capacity Constraints
    We also asked respondents to identify the major factors expected to constrain their organizations’ production capacity over the next five years. This year, the most frequently indicated factors (by both CMOs and biomanufacturers combined) were:
    • “Facility constraints” (52.4%, relatively unchanged from 52.9% last year)
    • “Inability to hire new, experienced technical and production staff”
    • “Inability to hire new, experienced scientific staff”
    • “Physical capacity of downstream purification equipment”
    • “Inability to retain experienced technical and production staff”
    Physical facility-related constraints and inability to hire and retain key staff personnel were the most severe factors affecting projection of future capacity constraints. It is somewhat surprising or paradoxical that the lowest-reported factor at 6.3% was “Production problems with downstream purification.” Downstream operations generally are still perceived as a relative bottleneck area, compared to upstream operations. But downstream was reported as a significant equipment problem: 28.6% cited “Physical capacity of downstream purification equipment.” This suggests that downstream problems are associated with specific equipment limitations. This is consistent with other study data showing chromatography areas to be a serious bottleneck.

    We do note that the two groups — biotherapeutic manufacturers and CMOs — differed significantly in most areas considered as potentially creating future capacity constraints. For example, CMOs have fewer concerns than developers in areas including:
    “Facility Constraints,” “Inability to hire new, experienced scientific staff,” and “Physical capacity of downstream purification equipment.”

    While initially it seems surprising that CMOs would have fewer concerns over the physical capacity of downstream purification equipment, it may be that they are more confident that those equipment issues will be taken care of in the next five years, particularly given their intense focus on innovation in this exact area.

    Meanwhile, CMOs have higher levels of concerns over those of developers in only a few areas, including: “Inability to retain experienced technical and professional staff.” CMOs are apparently having more problems retaining than hiring staff and “Costs associated with downstream production.”

    That last concern may be related to the enthusiasm with which CMOs have adopted disposable technology. With regard to cost, biomanufacturers and CMOs accepted the vision of disposables as lowering capital investment compared with stainless steel. However the reality of this decision has begun to go against many biomanufacturers, with high single-use production costs that are not competitive compared with operations in already-depreciated facilities using stainless steel. We expect that in time, the costs of disposable technologies will decline, allowing cheaper solutions even compared with depreciated legacy stainless steel systems.

    The data reflects a number of core differences between CMO and biomanufacturer focus. CMOs are critically focused around managing cost and, and successfully implementing efficiency solutions for their products, in order to maximize their profits.
    Biomanufacturers typically take a longer view of the process, being more likely to develop platform-based approaches that can be used for a number of their candidate molecules. CMOs have fewer concerns about analytics, drug product release and capacity since they rely on the client (the biomanufacturer) for developing and transferring appropriate methods and specifications and because CMOs typically pass on capacity and purification costs.

    We continue to see CMOs being an important lead indicator for concerns because of this tight focus on operations. The increased focus on capacity and purification was seen in CMOs in 2012 data, as well as 2011 data, indicating they may see these issues earlier than biotherapeutic innovators, which are typically focused on a much wider range of issues but less focused on operational considerations. CMOs are also seeing that the overall system needs optimization, rather than just a focus on particular unit operations and processes. Such a trend is expected to become more important as biogenerics and biosimilars become increasingly prevalent in the industry. 

    References
    1. 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates, April 2013.

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc. (www.bioplanassociates.com), a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports. He can be reached at elanger@bioplanassociates.com and 301-921-5979.
    Related Searches
    • contract manufacturing organizations
    • Development
    • CMO
    • Manufacturing
    Suggested For You
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    Mogene Mogene
    TFF Expands Engagement with Experic TFF Expands Engagement with Experic
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Embedding your Drug Strategy Within a Solid Foundation for Success Embedding your Drug Strategy Within a Solid Foundation for Success
    Vetio Animal Health Vetio Animal Health
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

    Related Bio News & Views

    • Biosimilars | Process Development
      Biopharm Executives Point to Better CMO Performance

      Biopharm Executives Point to Better CMO Performance

      Better process control and increased adoption of single-use systems played a part in improving downstream manufacturing
      Eric S. Langer, BioPlan Associates, Inc. 10.14.14

    • Biosimilars | Logistics | Supply Chain | Validation

      Outsourcing Media and Buffer Prep

      Facilities are evaluating ways to reduce bottlenecks, lower risks, eliminate logistics and inventory costs
      Eric S. Langer, BioPlan Associates, Inc. 09.08.14

    • Biosimilars | Clinical Trials | Drug Delivery | Fill/Finish

      Alvotech and Finesse Enter Bio-Manufacturing Pact

      Catalent, CiRA in regenerative therapy pact
      04.03.14


    • Biosimilars | cGMP Manufacture | Toxicology

      Too Much CMO Capacity?

      ...
      Eric A. Langer, BioPlan Associates 03.07.14

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development

      CMOs Demanding More Innovations

      Chromatography and single-use equipment top list
      Eric Langer , BioPlan Associates 11.13.13

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    • Precision Medicine Group Acquires Project Farma
    • A New Era Of Vaccine And Biologic Drug Development
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    What You're Reading on Happi.com
    Amyris Named a Top Social & Environmental Impact Company
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login